Manny Litchman, M.D.
Dr. Litchman is the President and CEO of Arvinas. Previously, he served as the Senior Vice President and Global Program Head at Novartis Pharmaceuticals for the CTL019 project, a collaboration with the University of Pennsylvania (Penn) involving personalized cell and gene therapy. He began his pharmaceutical career in oncology clinical research at Hoffmann-La Roche, then transitioned to Sandoz/Novartis, where he held positions of increasing responsibility in oncology development. From 2000-2001, he served as a Senior Equity Analyst at Ursus Capital, a biotechnology hedge fund. He then returned to Novartis, where he was the Head of Oncology Business Development & Licensing until the execution of the Penn deal in 2012.
Dr. Litchman obtained his B.A. in German Literature from Princeton University and his M.D. from Yale University School of Medicine. He completed his internal medicine residency and his hematology-oncology fellowship at New York Presbyterian Hospital / Weill Cornell Medical Center.
John G. Houston, Ph.D.
Dr. Houston is the President of R&D and CSO. Previously he was the SVP of Specialty Discovery at Bristol Myers Squibb. He spent over 18 years at BMS in roles of increasing responsibility and had accountability for all Discovery Biology disease teams as well as various Discovery technology departments and was site head of the BMS Connecticut facility. He was a member of the BMS R&D Executive Leadership team and chaired the Target Portfolio Committee which had governance oversight in the discovery space. With his teams, and his research colleagues, he progressed over 200 compounds into early development, several of which advanced into late stage clinical trials and beyond.
He was also the principal architect and driver of the ‘Leveraging Technology’ initiative at BMS which oversaw the design and implementation of an industry leading integrated lead discovery and optimization process. This initiative created revolutionary changes in the discovery process at BMS with significant improvements in capacity, speed and cost control resulting in marked increases in research productivity and success rates.
John has over 28 years of experience in the pharmaceutical industry and prior to joining Bristol-Myers Squibb, Dr. Houston worked at Glaxo Welcome Research and Development in the UK, where he served as head of the Lead Discovery Unit.
Dr Houston obtained his B.Sc degree in Medical Microbiology from Glasgow University and obtained his Ph.D. with Professor Brian Catley in Microbial Biochemistry from Heriot-Watt University, Edinburgh. John also completed post-doctoral studies on an MRC grant with Professor Julia Douglas at Glasgow University.
Sean Cassidy, M.B.A., C.P.A.
Mr. Cassidy is the Chief Financial Officer of Arvinas. He has over 20 years of experience in the life sciences industry, including serving as Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation (NASDAQ: CRGN), a clinical stage biopharmaceutical company; and Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next generation DNA sequencing instruments and reagents.
Earlier in his career, Mr. Cassidy served at Deloitte, one of the big four public accounting firms with a broad base of clients in the healthcare space. Mr. Cassidy is also the Treasurer of the Friends of Yale New Haven Children’s Hospital, a nonprofit organization that helps improve the health and well-being of pediatric patients and their families.
Mr. Cassidy holds an M.B.A. and B.S. from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.
Andy Crew, Ph.D.
Dr. Crew is the Vice President, Chemistry at Arvinas and is responsible for development of the Arvinas PROTAC/HyT technology and its deployment to therapeutic programs. He has 26 years of pharmaceutical/biotechnology experience, most recently serving at OSI/Astellas, where he led multidisciplinary project teams to deliver clinical development and back-up agents into the oncology pipeline against targets including mTORC1/2, PTK2, cKit and KDR. Prior to OSI/Astellas, Dr. Crew was a group leader at Tularik, UK where he enjoyed a heavy structure-based focus on drug discovery against the FXa, FVIIa and uPA serine proteases for the treatment of cardiovascular disease and cancer.
Earlier in his career, Dr. Crew served at BASF/Knoll working on GPCR targets such as dopamine D1, D2 and serotonin 5-HT1A receptors for the atypical treatment of schizophrenia.
Dr. Crew received his Ph.D. from the University of Liverpool, UK.
Robert Kleinfield, Ph.D.
Dr. Kleinfield is the Chief Development Officer at Arvinas. He brings over 20 years of product development and project leadership experience to the Company, having led programs in oncology, metabolic diseases and anti-infective therapeutic areas in a variety of pharmaceutical settings.
Prior to joining Arvinas, Dr. Kleinfield spent more than six years with Takeda Pharmaceuticals leading global programs for a number of oncology assets, including kinase inhibitors, immuno-stimulators and protein-modifying enzymes. In this role, he was instrumental in introducing novel translational approaches into the early development space and implementing innovative clinical designs. Prior to Takeda, he worked for five years at Wyeth, where he played pivotal roles in the development of Torisel® and Bosulif®, having led teams overseeing the global Phase 3 programs and subsequent registration of these assets, among others. Dr. Kleinfeld began his career at Bayer, where he had multiple positions of increasing responsibility over 10 years, including Project Lead for anti-infective assets, including Cipro® and Avelox®; metabolic disease assets, including Precose® and Trasylol®; and early stage oncology assets. His last position at Bayer, Germany, was VP and Head of Global Clinical Project Management.
Dr. Kleinfield earned his undergraduate degree at University of Rochester (magna cum laude) and his Ph.D. at the University of Pennsylvania. He subsequently completed postdoctoral fellowships at the University of Pennsylvania and Massachusetts General Hospital/Harvard Medical School.
Marcia Dougan Moore, M.P.H.
Ms. Dougan Moore is the Vice President of Development Operations at Arvinas. She has more than 25 years of experience in the pharmaceutical and biotechnology industries, and is currently a member of the Product Development Peer Review Committee at the Cancer Prevention and Research Institute of Texas. Over the course of her career, Ms. Dougan Moore has worked across all phases of drug development including IND-enabling activities, clinical trials (Phases 1-3) and in the post-marketing setting. Previously, she served as Director, Strategic Drug Development and Project Management at Alexion Pharmaceuticals, where she successfully transitioned products into clinical development. Ms. Dougan Moore was also a key contributor to the success of several regulatory filings.
She began her career at Bristol-Myers Squibb where she held positions of increasing responsibility in clinical research, new market planning and external development. She was also a member of the Bristol-Myers Squibb Foundation’s Oncology Unrestricted Grants Committee.
Ms. Dougan Moore received her M.P.H. from Yale University and B.S. from Bates College.
Angela Shen, M.D., M.B.A.
Dr. Shen is the Chief Medical Officer of Arvinas. She brings extensive experience in clinical development, medical affairs and business development to the Company, having led clinical programs in oncology in a variety of pharmaceutical settings.
Prior to joining Arvinas, Dr. Shen was a Global Clinical Program Head at Novartis, where she helped launch the CTL019 (CART-19) Cell & Gene Therapy program. As Head of Clinical Evaluation for the Oncology Business Development group, she was extensively involved in licensing new compounds to strengthen the Novartis Oncology pipeline, including CTL019. Prior to that, Dr. Shen served as clinical lead at Novartis and Exelixis for multiple new oncology assets in development, and held a Medical Affairs role at Johnson & Johnson.
Dr. Shen earned her B.S. at Rensselaer Polytechnic Institute and went on to receive her M.D. from Albany Medical College in New York. Her postdoctoral experience included general surgery residency at Staten Island University Hospital, North Shore-LIJ Health System. She obtained her M.B.A., with a concentration in finance and management, from New York University.
Ian Taylor, Ph.D.
Dr. Taylor is the Vice President, Biology at Arvinas. He came to the Company after nearly 10 years at Pfizer Oncology, most recently as an Early Development Team Leader. In this role, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. His initial role at Pfizer Oncology was as Senior Director of Translational Oncology. In this role, he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages.
Prior to Pfizer, Dr. Taylor worked at Bayer Healthcare, Pharmaceuticals, holding positions of increasing responsibility including Vice President of Cancer Biology. In this position, he led the department responsible for all biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis. During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib.
Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).